• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director

    2/20/25 6:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care
    Get the next $NIVF alert in real time by email

    Company Granted Request to Continue its Listing on Nasdaq

    Appoints Thorain Ko to Lead Business Development Initiatives

    BANGKOK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Stock Market, subject to specific conditions. Additionally, the Company announced the appointment of Mr. Thorain Ko as Business Development Director to drive its expansion initiatives.

    Nasdaq Listing Update

    The Panel has granted NewGen's request to continue its listing on the Nasdaq Stock Market subject to several conditions that must be met within specified time frames. The Company has already made progress on its compliance plan, including carrying out a reverse split on February 11, 2025 and achieving compliance with the shareholders' equity minimum for listing on the Nasdaq Capital Market ahead of schedule through note conversions. The Company intends to apply for transition to the Nasdaq Capital Market on or before February 26, 2025.

    Appointment of Business Development Director

    In a strategic move to strengthen its management team, NewGen has appointed Mr. Thorain Ko as Business Development Director. Mr. Ko will spearhead the Company's efforts to develop its recently announced lifetime egg-freezing business in China and broader Asian markets, while also driving sales initiatives across the Company's fertility service offerings.

    Mr. Ko brings over 30 years of experience in business development, healthcare, and direct-selling to NewGen. Most recently, he served as a Sales and Marketing Director at USANA Health Sciences, specializing in nutritional supplements, skincare, and weight management products. Previously, Mr. Ko held leadership positions at Jeunesse Global Group Ltd. as Marketing Manager and at HEC International, LLC as Operations Director. Mr. Ko holds a Bachelor of Laws (LLB) from the University of London and a Master of Corporate Governance (MCG) from Hong Kong Polytechnic University.

    Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen, commented, "We are pleased with the Panel's decision to grant our continued listing request and appreciate their recognition of our progress in meeting Nasdaq's requirements. As we work to complete our compliance plan, we are simultaneously strengthening our management team with the addition of Mr. Ko, whose extensive experience in healthcare business development across Asia will be instrumental in driving our growth initiatives, particularly in our lifetime egg-freezing business. These developments reflect our commitment to creating value for shareholders while expanding access to fertility services across Asia."

    About NewGen

    NewGen is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. With a mission to aid couples and individuals in building families regardless of fertility challenges, NewGen has dedicated itself to creating increased access to infertility treatment and providing comprehensive fertility services for its customers. NewGen's management team collectively has over a decade of experience in the fertility industry. NewGen's clinics are located in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions, respectively. To learn more, visit www.newgenivf.com. The information contained on, or accessible through, NewGen's website is not incorporated by reference into this press release, and you should not consider it a part of this press release.

    Forward-Looking Statements

    This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations, business strategy, and financial condition. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release. You should carefully consider the foregoing factors and the other risks and uncertainties described in the Company's annual report on Form 20-F and other documents filed or to be filed by the Company with the SEC from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC's website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

    Investor Relations Contact

    ICR, LLC

    Robin Yang

    Phone: +1 (212) 537-4406

    Email: [email protected]



    Get the next $NIVF alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NIVF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NIVF
    SEC Filings

    View All

    Amendment: SEC Form F-1/A filed by NewGenIvf Group Limited

    F-1/A - NewGenIvf Group Ltd (0001981662) (Filer)

    10/10/25 4:19:53 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    10/9/25 7:42:17 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form F-1 filed by NewGenIvf Group Limited

    F-1 - NewGenIvf Group Ltd (0001981662) (Filer)

    9/18/25 2:32:01 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zacks Small-Cap Research Initiates Coverage on NewGen

    BANGKOK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced that Zacks Small-Cap Research ("Zacks") has initiated equity research coverage on the Company. The full equity research report is available on the Zacks website here. About NewGenNewGenIVF Group is a tech-forward, diversified, multi-jurisdictional high-growth entity capitalizing on emerging opportunities across real estate development, digital asset innov

    10/10/25 9:20:55 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGen Establishes New Joint Venture Dedicated to Real Estate Development in UAE

    An agreement signed between NewGen and BNW will establish a joint venture to develop NewGen's recently acquired plot of land in Ras Al Khaimah's Beach District, UAE Feasibility studies indicate potential net returns for NewGen of up to US$67 million BANGKOK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that it has established a new joint venture dedicated to the development of its strategic plot of land in Ras Al Khaimah's Beach District, UAE. The joint venture marks a significant milestone in Ne

    10/8/25 9:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGen Reports Total Gain from IP Acquisition of $17.9 Million for FY 2025

    Valuation Report from Big Four Global Accounting Firm Sets Fair Value of Acquired IP at US$17.9 Million and Boosts NAV per share by about US$8.9 Acquisition Will Aid NewGen's Transition From IVF Services Provider to Technology-driven Innovator BANGKOK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that it has received an independent valuation report (the "Report") from a Big Four global accounting firm of its recently acquired advanced cytometry intellectual property (the "IP"), the acquisition of

    10/6/25 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Chardan Capital Markets Llc claimed ownership of 1,569,000 units of Class A Ordinary Shares (SEC Form 3)

    3 - NewGenIvf Group Ltd (0001981662) (Issuer)

    11/13/24 9:16:27 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Leadership Updates

    Live Leadership Updates

    View All

    NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director

    Company Granted Request to Continue its Listing on NasdaqAppoints Thorain Ko to Lead Business Development Initiatives BANGKOK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Stock Market, subject to specific conditions. Additionally, the Company announced the appointment of Mr. Thorain Ko as Business Development Director to drive its expansion initiatives. Nasdaq Listing UpdateThe Pane

    2/20/25 6:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    12/5/24 8:23:57 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    11/13/24 9:19:27 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    10/10/24 3:39:26 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care